Lv1
30 积分 2022-01-12 加入
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
1天前
待确认
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements
1天前
已完结
Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy
3天前
已完结
Precision Immunotherapy for STK11/KEAP1-Mutant NSCLC
4天前
已完结
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer
22天前
已完结
POSing the question: MARIPOSA-2, do the ends justify the means?
24天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial
1个月前
已完结
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
2个月前
已完结
A randomized double-blind trial of TQB2450 with or without anlotinib in pretreated driver-negative non-small cell lung cancer
2个月前
已完结
皖公网安备34019202002308
